Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review

Phillippa J Poole, Peter N Black

Abstract

Objective To assess the effects of oral mucolytics in adults with stable chronic bronchitis and chronic obstructive pulmonary disease.

Design Systematic review of randomised controlled trials that compared at least two months of regular oral mucolytic drugs with placebo.

Main outcome measures Exacerbations, days of illness, lung function, adverse events.

Results Compared with placebo, the number of exacerbations was significantly reduced in subjects taking oral mucolytics (weighted mean difference −0.07 per month, 95% confidence interval −0.08 to −0.05, P < 0.0001). Based on the annualised rate of exacerbations in the control subjects of 2.7 a year, this is a 29% reduction. The number needed to treat for one subject to have no exacerbation in the study period would be 6. Days of illness also fell (weighted mean difference −0.56, −0.77 to −0.35, P < 0.0001). The number of subjects who had no exacerbations in the study period was greater in the mucolytic group (odds ratio 2.22, 95% confidence interval 1.93 to 2.54, P < 0.0001). There was no difference in lung function or in adverse events reported between treatments.

Conclusions In chronic bronchitis and chronic obstructive pulmonary disease, treatment with mucolytics is associated with a reduction in acute exacerbations and days of illness. As these drugs have to be taken long term, they could be most useful in patients who have repeated, prolonged, or severe exacerbations of chronic obstructive pulmonary disease.

Introduction

At least half of smokers will develop chronic bronchitis,¹ and up to 15% will develop limiting symptoms from chronic obstructive pulmonary disease.² People with chronic bronchitis or chronic obstructive pulmonary disease may experience recurrent exacerbations with worsening symptoms or greater volume or purulence of sputum. These exacerbations contribute to morbidity and poorer health² as well as to increased healthcare costs.³ Although these exacerbations can be treated with antibiotics or steroids, it would be useful to have other treatments that reduced the frequency and duration of acute exacerbations. Mucolytics increase the expectoration of sputum by reducing its viscosity or hypersecretion.⁴ Some are also antioxidants.⁵ These drugs might be of benefit in reducing exacerbations of chronic obstructive pulmonary disease. In some European countries, mucolytics are widely prescribed in the belief that they reduce the frequency of exacerbations or symptoms in patients with chronic bronchitis. However, in the United Kingdom and Australasia, mucolytics are used infrequently because they are perceived to be ineffective. Two oral mucolytics are currently available in the United Kingdom (carbocisteine and mecodeistine)⁶ and one in New Zealand (bromhexine). These drugs, however, are not funded in either country for adults with chronic obstructive pulmonary disease.

We conducted a systematic review to determine, firstly, if treatment with mucolytics reduced the frequency of exacerbations or days of illness in people with chronic bronchitis or chronic obstructive pulmonary disease and, secondly, to determine if mucolytics improve lung function or increase adverse events.

Methods

We did the first Cochrane systematic review on this topic in 1997 and updated it in 1999 using similar methods.⁸ We identified abstracts using the Cochrane Airways Group register. The register has been compiled from Medline, Embase, CINAHL, and hand searching of respiratory journals and meeting abstracts. We searched the register using the following terms: (chronic bronchitis or chronic obstructive pulmonary disease) and (mucolytics or N-acetylcysteine or bromhexine or S-carboxymethylcysteine or ambroxol or sobrerol or iodinated glycerol).

From the abstracts of studies identified by this search strategy, we identified studies for full text review. In addition, we checked the reference lists of all the papers and reviews we obtained for any other relevant articles. We contacted researchers in the field and pharmaceutical companies asking for relevant material. We each independently selected trials for inclusion in the review. Disagreement over inclusion was resolved by discussion. Papers published in languages other than English were assessed with the help of four translators. When we needed more data or clarification, we wrote at least twice to authors and pharmaceutical companies.
Details of studies included in systematic review

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>No of patients</th>
<th>Clinical criteria (mean lung function)</th>
<th>Mean age (years)</th>
<th>% of smokers</th>
<th>Length of study (months)</th>
<th>Intervention</th>
<th>Quality score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alegre 1996</td>
<td>Italy</td>
<td>682</td>
<td>Chronic bronchitis (FEV1, 65% predicted)</td>
<td>60.1</td>
<td>73 current</td>
<td>6</td>
<td>Carbocisteine 750 mg thrice daily</td>
<td>5</td>
</tr>
<tr>
<td>Babolini 1997</td>
<td>Italy</td>
<td>744</td>
<td>Chronic bronchitis (FEV1, 218 l)</td>
<td>NA</td>
<td>64.3</td>
<td>6</td>
<td>Acetylcysteine 200 mg twice daily</td>
<td>4</td>
</tr>
<tr>
<td>Boman 1983</td>
<td>Sweden</td>
<td>259</td>
<td>Chronic bronchitis (FEV1, 80% predicted)</td>
<td>51.9</td>
<td>108</td>
<td>6</td>
<td>Acetylcysteine 200 mg twice daily</td>
<td>2</td>
</tr>
<tr>
<td>Bontognali 1991</td>
<td>Italy</td>
<td>60</td>
<td>Chronic bronchitis (NA)</td>
<td>57</td>
<td>NA</td>
<td>3</td>
<td>Citiolone 400 mg twice daily</td>
<td>3</td>
</tr>
<tr>
<td>Borghi 1981</td>
<td>Italy</td>
<td>21</td>
<td>Chronic bronchitis (FEV1, 38.2 l)</td>
<td>45.3</td>
<td>NA</td>
<td>6</td>
<td>Acetylcysteine 200 mg twice daily</td>
<td>3</td>
</tr>
<tr>
<td>Castiglioni 1986</td>
<td>Italy</td>
<td>706</td>
<td>Chronic bronchitis (FEV1, 75% predicted)</td>
<td>56.5</td>
<td>73.5</td>
<td>3</td>
<td>Sobrerol 300 mg twice daily</td>
<td>3</td>
</tr>
<tr>
<td>Cegla 1988</td>
<td>Italy</td>
<td>180</td>
<td>Chronic bronchitis (FEV1, 215 l)</td>
<td>51.1</td>
<td>36 current</td>
<td>24</td>
<td>Ambroxol 75 mg daily</td>
<td>3</td>
</tr>
<tr>
<td>Cremonini 1986</td>
<td>Italy</td>
<td>41</td>
<td>Chronic bronchitis (FEV1, 59% predicted)</td>
<td>60.8</td>
<td>NA</td>
<td>3</td>
<td>Lattostine 50 mg thrice daily</td>
<td>3</td>
</tr>
<tr>
<td>Ekberg-Jansson 1999</td>
<td>Sweden</td>
<td>697</td>
<td>Chronic bronchitis (FEV1, 73% predicted)</td>
<td>58</td>
<td>100</td>
<td>6</td>
<td>Isobutyrylcysteine 300 mg thrice daily</td>
<td>3</td>
</tr>
<tr>
<td>Grassi 1994</td>
<td>Italy</td>
<td>135</td>
<td>Chronic bronchitis (FEV1, 57% predicted)</td>
<td>61.8</td>
<td>78</td>
<td>3</td>
<td>Carbocelesteine-sobrerol daily</td>
<td>4</td>
</tr>
<tr>
<td>Grassi 1996</td>
<td>Italy</td>
<td>80</td>
<td>Chronic bronchitis (NA)</td>
<td>60.9</td>
<td>NA</td>
<td>6</td>
<td>Acetylcysteine 600 mg three times/week</td>
<td>3</td>
</tr>
<tr>
<td>Grillage 1985</td>
<td>United Kingdom</td>
<td>109</td>
<td>Chronic bronchitis (PEFR, 232 l/min)</td>
<td>NA</td>
<td>NA</td>
<td>6</td>
<td>Carbocisteine 750 mg thrice daily</td>
<td>4</td>
</tr>
<tr>
<td>Hansen 1994</td>
<td>Denmark</td>
<td>153</td>
<td>Chronic bronchitis (FEV1, 2.34 l)</td>
<td>51.4</td>
<td>100</td>
<td>5</td>
<td>Acetylcysteine 600 mg twice daily</td>
<td>3</td>
</tr>
<tr>
<td>Jackson 1984</td>
<td>United Kingdom</td>
<td>155</td>
<td>Chronic bronchitis (NA)</td>
<td>63</td>
<td>88</td>
<td>3</td>
<td>Acetylcysteine 200 mg thrice daily</td>
<td>4</td>
</tr>
<tr>
<td>McGavney 1985</td>
<td>United Kingdom</td>
<td>181</td>
<td>Chronic bronchitis (FEV1, 0.86 l)</td>
<td>63.4</td>
<td>99</td>
<td>5</td>
<td>Acetylcysteine 200 mg thrice daily</td>
<td>4</td>
</tr>
<tr>
<td>Meister 1986</td>
<td>Germany</td>
<td>252</td>
<td>Chronic bronchitis (PEFR, 303 l/min)</td>
<td>57.2</td>
<td>88</td>
<td>6</td>
<td>Acetylcysteine 300 mg twice daily</td>
<td>3</td>
</tr>
<tr>
<td>Meister 1999</td>
<td>Germany</td>
<td>246</td>
<td>Chronic bronchitis (FEV1, 76% predicted)</td>
<td>57.2</td>
<td>88</td>
<td>6</td>
<td>Myrtal 300 mg thrice daily</td>
<td>4</td>
</tr>
<tr>
<td>Nowak 1999</td>
<td>Europe</td>
<td>313</td>
<td>Chronic obstructive pulmonary disease (FEV1, 60% predicted)</td>
<td>57</td>
<td>NA</td>
<td>8</td>
<td>Acetylcysteine 600 mg twice daily</td>
<td>2</td>
</tr>
<tr>
<td>Oliveni 1987</td>
<td>Italy</td>
<td>240</td>
<td>Chronic bronchitis (NA)</td>
<td>NA</td>
<td>NA</td>
<td>6</td>
<td>Ambroxol 75 mg daily</td>
<td>2</td>
</tr>
<tr>
<td>Parr 1987</td>
<td>United Kingdom</td>
<td>526</td>
<td>Chronic bronchitis (NA)</td>
<td>63</td>
<td>88</td>
<td>6</td>
<td>Acetylcysteine 200 mg thrice daily</td>
<td>4</td>
</tr>
<tr>
<td>Petta 1999</td>
<td>Italy</td>
<td>169</td>
<td>Chronic obstructive pulmonary disease (FEV1, 58% predicted)</td>
<td>66</td>
<td>28 current</td>
<td>6</td>
<td>Acetylcysteine 600 mg daily</td>
<td>3</td>
</tr>
<tr>
<td>Petty 1990</td>
<td>United States</td>
<td>367</td>
<td>Chronic bronchitis (FEV1, 45% predicted)</td>
<td>65</td>
<td>NA</td>
<td>2</td>
<td>Iodinated glycerol 60 mg four times daily</td>
<td>5</td>
</tr>
<tr>
<td>Rasmussen 1988</td>
<td>Sweden</td>
<td>116</td>
<td>Chronic bronchitis (PEFR, 305 l/min)</td>
<td>58.9</td>
<td>100</td>
<td>6</td>
<td>Acetylcysteine 300 mg twice daily</td>
<td>3</td>
</tr>
</tbody>
</table>

NA=not available. FEV1=forced expiratory volume in one second. PEFR=peak expiratory flow rate.

The included studies were randomised, double blind, placebo controlled studies of oral mucolytics taken regularly for at least two months. We excluded trials of inhaled mucolytics; combinations of mucolytics with antibiotics or bronchodilators; deoxyribonucleases; and proteases such as trypsins. Participants were adults (>20 years) with chronic bronchitis or chronic obstructive pulmonary disease defined according to Medical Research Council, European Respiratory Society, or American or British Thoracic Society guidelines. Studies on people with asthma or cystic fibrosis were excluded.

The primary outcome measures were the number of acute exacerbations (including the number of participants with no exacerbations in the study period) and days of illness (defined as days in bed, days off work, or days when the participant was unable to undertake normal activities). Days taking antibiotics were also assessed. The secondary outcome measures were measures of lung function (including forced expiratory volume in one second, forced vital capacity, and peak expiratory flow rate) and adverse effects of treatment.

We used summary statistics rather than individual patient data. We assessed the quality of randomisation, blinding, and description of dropouts using the five point Jadad scale. Exacerbation rates and days of illness were calculated per patient per month by dividing the number of events by the number of participants and the number of months of the study. A fixed effects model was used. We analysed continuous data using the weighted mean difference (except for forced expiratory volume, percentage change in forced expiratory volume, and peak expiratory flow rate, which were combined by using a standardised mean difference because of the different scales used). The Peto odds ratio was used for dichotomous data. We used the Breslow-Day test for heterogeneity (variability in study results). The meta-analysis was done with Review Manager software (version 4.0 1999, Cochrane Collaboration and Update Software).

Results

We identified over 400 trials from the computer searches. After excluding studies that were clearly ineligible, we obtained the full text of 77 papers for independent scrutiny by the authors. In two unpublished studies, the information used was obtained from the abstract and from the pharmaceutical company (R Meister, long term treatment with acetylcysteine retard, 1986). Twenty seven trials studied double blind placebo controlled treatment with an oral mucolytic drug for at least eight weeks. Four of these were excluded because they did not provide information on the primary outcome. The remaining 23 studies are included in the review (Meister). Twenty one studied people with chronic bronchitis and two studied people with chronic obstructive pulmonary disease (table). All 23 randomised controlled trials had a Jadad quality score of at least 2 out of 5, and 20 had a score of 3 or more.

Exacerbations

Regular use of mucolytics was associated with a reduction of 0.07 exacerbations per patient a month (95% confidence interval –0.08 to –0.05, P<0.0001, fig).
erbation rates with the thiol donor, isobutyrylcysteine. Other drugs, there was no significant reduction in exacerbations that included this study and assumed that both mucolytics was reduced by 0.53 a month (−0.76 to −0.31, P<0.0001).

Lung function
In the few studies that reported this outcome, the differences in both forced expiratory volume in one second and forced vital capacity between subjects receiving mucolytic drugs and placebo were small and not significant. We combined measurements of airflow (forced expiratory volume, percentage change in forced expiratory volume, peak expiratory flow rate and change in peak flow rate) using a standardised mean difference, to increase the power of the analysis, but this also showed no significant difference between treatment and placebo (fig 2).

Adverse events
Adverse events were usually mild and self limiting. The meta-analysis of total adverse events showed a significant effect in favour of mucolytic drugs (odds ratio 0.79, 0.67 to 0.93). However, this analysis does not include data from three studies that had more events...
than subjects and could therefore not be analysed using the Peto odds ratio method. If these three studies are included, there were 1890 adverse events in 2450 subjects taking mucolytic drugs and 1882 events in 2453 subjects taking placebo (mean of 0.77 events per subject in both groups). There is, therefore, probably no difference between mucolytic and placebo treatments in terms of the total number of adverse events.

Discussion

Our systematic review shows that mucolytic drugs have a modest but significant effect on exacerbation rates in people with chronic bronchitis and chronic obstructive pulmonary disease. The reduction of 0.07 exacerbations per month is 29% lower than the rate in the control group. On the basis of the annualised exacerbation rate (weighted for study size) of 2.7 per patient per year in the control group, mucolytic treatment was associated with a reduction of 0.79 exacerbations per patient per year. This approach, however, tends to overestimate the annual number of exacerbations as more exacerbations occur during winter, when most of these studies were done.

Robustness of results

We found significant heterogeneity in the precision of the measure of the effect size among the studies in this analysis (P<0.0001). To explore possible reasons for this, we performed subgroup analysis using previously determined criteria. These criteria were the baseline forced expiratory volume in one second (% predicted), the type and dose of mucolytic, whether subjects were included because they had a history of exacerbations, the duration of treatment, and the country in which the study was conducted. Significant heterogeneity was eliminated in the analysis of the two studies in which forced expiratory volume was less than 50% predicted and in the analysis of the 11 studies not conducted in Italy. Most of the heterogeneity is not explained.

Despite this, we consider that the finding that mucolytic drugs reduce the exacerbation rate is robust. Fewer exacerbations with mucolytic drugs were seen in all 20 studies, and there was internal consistency between the outcomes. In addition, there was no significant heterogeneity for the outcome “subjects with no exacerbations in the study period.” Subjects who received mucolytic drugs were twice as likely to have no exacerbation in the study than if they had received placebo. The effect of mucolytics on days of illness (0.56 days less per subject per month) was greater than the effect on number of exacerbations, but is roughly what would be expected clinically as an exacerbation usually lasts for several days. This finding was based on six studies, although there was some heterogeneity between them (P=0.0034). However, there were four other studies with mean values reported (but no SD), and these all showed a reduction in days of illness with mucolytics that was between 0.3 and 3.9 days per subject per month. Subjects took antibiotics for less time as well. These findings suggest that the exacerbations that do occur are either less serious or less prolonged.

Hospital admission rates

None of the studies reported the effect of treatment with mucolytics on hospital admission for chronic obstructive pulmonary disease. It is important that this outcome is included in future studies as it contributes greatly to the costs of treating severe chronic obstructive pulmonary disease. Studies of other types of treatment for chronic obstructive pulmonary disease have shown an effect on hospital admissions. A recent randomised controlled trial has shown that pulmonary rehabilitation reduces hospital bed days, mainly by reducing length of stay. An immunomodulatory agent OM-85 BV has been shown to reduce the number of hospital admissions, even though it did not affect the number of exacerbations.

Definition of disease

Most of the studies were conducted many years ago on patients with chronic bronchitis, and most used the Medical Research Council definition “the presence of cough and sputum for three or more months in two consecutive years.” More recent studies have focused on patients with chronic obstructive pulmonary disease—that is, those with irreversible airflow obstruction. Nevertheless, in the earlier chronic bronchitis studies the percentage of smokers was high and many patients had evidence of some airflow limitation. It is likely, therefore, that today many would be defined as having chronic obstructive pulmonary disease (see table). The reduction in exacerbations seen with mucolytics in the two studies in chronic obstructive pulmonary disease was at least as large as that seen in subjects with chronic bronchitis. Thus, we feel justified in including studies of both chronic bronchitis and chronic obstructive pulmonary disease in this review.

How do the drugs work?

Although the mechanism(s) by which mucolytic drugs reduce exacerbation rates and days of illness cannot be determined from this review, some hypotheses may be generated. Acetylcysteine was used in 12 of the studies. Although this drug has mucolytic and antioxidant effects, the reduction in exacerbation rates with this drug was virtually identical to that seen with the other mucolytics, when they were examined as a group. Isotretinylcysteine is a derivative of acetylcysteine, and was promoted as an antioxidant thiol donor, yet the only study of this drug found no effect on exacerbations. This suggests that the beneficial effect of acetylcysteine is not due to its actions as a thiol donor. However, acetylcysteine may still act as an antioxidant in other ways.

Is treatment justified?

Clinicians and patients will need to judge for themselves whether the reductions in exacerbation rate and days of illness seen with mucolytic drugs are large enough to warrant daily treatment for at least three to six months a year. At recommended doses, the available mucolytics in United Kingdom cost over £200 a year. A short course of amoxicillin or prednisolone for one infective exacerbation costs around £2. In most of the studies, subjects had mild chronic obstructive pulmonary disease, defined by their degree of airways obstruction. A recent analysis of the cost effectiveness of acetylcysteine in chronic bronchitis suggested that the point at which the costs of
What is already known on this topic

Mucolytic drugs have properties that may be beneficial in chronic obstructive pulmonary disease.

These drugs are not prescribed in the United Kingdom and Australasia, although they are widely used in many other countries

Drugs that reduce exacerbations may reduce the morbidity and healthcare costs associated with progressively severe disease.

What this study adds

Regular use of mucolytic drugs for at least two months significantly reduces exacerbations and days of illness compared with placebo in patients with chronic bronchitis and chronic obstructive pulmonary disease.

Exacerbations that do occur may not be as severe, and the benefit may be greater in those with more severe disease.

Reductions are modest and treatment may not be cost effective.

treatment and non-treatment are equal was 0.6 fewer exacerbations per six months. In our review, exacerbations decreased by less than this (0.4 per six months). However, evidence from the two studies in patients with a mean forced expiratory volume less than 50% of predicted showed a reduction in the exacerbation rate of 0.13 per patient per month (0.8 per six months), suggesting that the benefit may be greater in those with more severe chronic obstructive pulmonary disease. Patients who have frequent or prolonged exacerbations or those who are repeatedly admitted to hospital with exacerbations of chronic obstructive pulmonary disease may also benefit more.

The reduction in the exacerbation rate per month was greater for the studies that lasted three months or less (0.15 per subject) than for those that lasted over three months (0.06 per subject). This suggests that the full benefit is seen early and does not increase subsequently. There was no evidence that mucolytics affected lung function in these studies or that they are unsafe.

Future randomised controlled trials should examine the value of mucolytic drugs in patients who have repeated, prolonged, or severe exacerbations or who are repeatedly admitted to hospital with exacerbations of chronic obstructive pulmonary disease. Use of mucolytics in acute exacerbations of chronic obstructive pulmonary disease should also be studied. All of these studies should include a measure of use of healthcare resources.

Paul Jones, Peter Gibson, Chris Cates, Anna Bara, and Karen Blackhall of the Cochrane Airways Group provided editorial and technical support. Silvana Campanella, Ruth Black, Klaus Lehner, and Daniela Scrinci translated for us. Further data were provided by Dompé farmaceutici, Zambon Group, and Douglas Pharmaceuticals.

Contributors: PNB initiated the protocol development. PJP and PNB collaborated on every step of both the first review and the update including protocol design, comparisons, data extraction, analysis, interpretation of results, and writing of the paper. PJP is the guarantor.

Funding: None.

Competing interests: None declared.


14 Robin BK, Ramirez O, Ohar JA. Inhaled glycerol has no effect on pulmonary function, symptom score, or sputum properties in stable chronic bronchitis. Chest 1996;109:348-52.


(Accepted 28 February 2001)